SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	1.32	2.24	23.9	60.88
Revenue Growth (YoY)	-	-40.94%	-90.63%	-60.73%	10.21%
Gross Profit	-	1.32	2.24	23.9	60.88
Selling, General & Admin	14.6	13.98	23.8	16.38	17.09
Research & Development	34.35	30.25	16.52	36.44	57.18
Total Operating Expenses	48.95	44.23	40.31	52.82	74.27
Operating Income	-48.95	-42.91	-38.08	-28.92	-13.39
Interest Income	1.43	1.29	0.58	0.07	0.02
Interest Expense	-0.24	-0.32	-0.32	-0.3	-0.29
Other Non-Operating Income (Expense)	61.04	7.84	-4.39	10.43	-3.48
Total Non-Operating Income (Expense)	62.23	8.81	-4.12	10.2	-3.75
Pretax Income	13.27	-34.11	-42.19	-18.72	-17.14
Provision for Income Taxes	-	-	-	-0.03	-
Net Income	13.27	-34.11	-42.19	-18.74	-17.14
Net Income to Common	13.27	-34.11	-42.19	-18.74	-17.14
Shares Outstanding (Basic)	19	9	6	4	3
Shares Outstanding (Diluted)	61	9	6	4	3
Shares Change (YoY)	562.28%	67.74%	26.86%	59.20%	1.21%
EPS (Basic)	0.22	-3.68	-7.64	-4.31	-6.30
EPS (Diluted)	-0.79	-3.68	-7.64	-4.31	-6.30
Free Cash Flow	-45.71	-34.63	-25.32	-25.63	-8.96
Free Cash Flow Per Share	-0.75	-3.74	-4.59	-5.89	-3.28
Gross Margin	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-3244.87%	-1700.56%	-120.97%	-22.00%
Profit Margin	-	-2579.03%	-1884.50%	-78.19%	-28.16%
FCF Margin	-	-2618.65%	-1130.71%	-107.20%	-14.71%
EBITDA	-45.87	-38.12	-34.33	-25.63	-11.74
EBITDA Margin	-	-2882.46%	-1533.28%	-107.20%	-19.28%
EBIT	-48.95	-42.91	-38.08	-28.92	-13.39
EBIT Margin	-	-3244.87%	-1700.56%	-120.97%	-22.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.14%	0.00%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q